Scotiabank analyst George Farmer maintained a Buy rating on Arcellx Inc (ACLX – Research Report) today and set a price target of $133.00. The company’s shares closed last Friday at $84.55.

Arcellx's Cancer Cell Therapy Shows Deep, Durable Responses With Manageable Safety Profile In Heavily Pretreated Blood Cancer Patients Arcellx's Phase 2 trial of anito-cel in relapsed multiple ...

On Sunday, Arcellx, Inc. (NASDAQ:ACLX) revealed new data from its Phase 2 pivotal iMMagine-1 study of anitocabtagene autoleucel (anito-cel) in patients with relapsed or refractory multiple myeloma ...

REDWOOD CITY, Calif., December 09, 2024--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with ...